村井純子

Murai Junko

所属機関・部署：
職名：特任准教授
その他の所属（所属・部署名・職名） (1件)：

ホームページURL (1件)： http://slfn11.iab.keio.ac.jp/

研究分野 (1件)：分子生物学

研究キーワード (4件)： SLFN11 , がん , DNAダメージ , 複製ストレス

競争的資金等の研究課題 (7件)：

全件表示

論文 (70件)：

Kohei Fujiwara, Masashi Maekawa, Yuki Iimori, Akane Ogawa, Takeshi Urano, Nobuaki Kono, Hiroyuki Takeda, Shigeki Higashiyama, Makoto Arita, Junko Murai. The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13. iScience. 2023. 26. 12. 108529-108529
Hidehiko Akashi, Nozomi Yachida, Haruka Ueda, Manako Yamaguchi, Kaoru Yamawaki, Ryo Tamura, Kazuaki Suda, Tatsuya Ishiguro, Sosuke Adachi, Yoshikazu Nagase, et al. SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. Molecular cancer therapeutics. 2023
Hiroshi Onji, Sota Tate, Tomohisa Sakaue, Nobuyuki Onishi, Takashi Matsumoto, Takashi Sugiyama, Shigeki Higashiyama, Junko Murai. Synergistic effects of PARP inhibitors by Schlafen 11 and BRCA2-deficiency through accumulation of single-strand DNA gaps behind a fork. 2023
Junko Murai, Michele Ceribelli, Haiqing Fu, Christophe E. Redon, Ukhyun Jo, Yasuhisa Murai, Mirit I. Aladjem, Craig J. Thomas, Yves Pommier. Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication. Molecular Cancer Therapeutics. 2023. 22. 8. 985-995
Junko Murai, Yves Pommier. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality. Cancer Research. 2023. 83. 8. 1173-1174

MISC (20件)：

Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Takahiro Uotani, Shinya Tani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, et al. THE FIRSR EVIDENCE FOR SLFN11 EXPRESSION AS AN INDEPENDENT PROGNOSTIC FACTOR FOR PATIENTS WITH ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY. GASTROENTEROLOGY. 2020. 158. 6. S777-S778
Yves Pommier, Junko Murai. PARP trapping and Schlafen 11. MOLECULAR CANCER RESEARCH. 2017. 15
Junko Murai, Sai-Wen Tang, Yves Pommier. Schlafen 11 (SLFN11) blocks RNA synthesis upon replicative damage, a novel mechanism for killing cancer cells in response to DNA damaging agents. CANCER RESEARCH. 2016. 76
Junko Murai, Yves Pommier. The combination of the PARP inhibitor talazoparib (BMN 673) with the ATR inhibitor VE-821 overcomes the drug resistance of Schlafen 11-deficient cells. CANCER RESEARCH. 2015. 75
Y. Pommier, J. Murai. CLASSIFICATION OF PARP INHIBITORS BASED ON PARP TRAPPING AND CATALYTIC INHIBITION, AND RATIONALE FOR COMBINATIONS. ANNALS OF ONCOLOGY. 2015. 26. 8-8

学位 (1件)：

経歴 (9件)：

全件表示

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

村井 純子